Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Reaffirmed by Needham & Company LLC

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “hold” rating reissued by analysts at Needham & Company LLC in a research note issued to investors on Friday, Benzinga reports.

LXRX has been the subject of several other research reports. StockNews.com raised shares of Lexicon Pharmaceuticals to a “sell” rating in a research note on Wednesday. SVB Leerink assumed coverage on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 30th. They set an “outperform” rating and a $5.00 price objective for the company. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 30th.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX stock opened at $1.74 on Friday. The firm has a market cap of $428.46 million, a price-to-earnings ratio of -2.10 and a beta of 1.38. The company has a debt-to-equity ratio of 1.07, a quick ratio of 5.58 and a current ratio of 5.60. The firm’s 50-day simple moving average is $2.10 and its two-hundred day simple moving average is $1.74. Lexicon Pharmaceuticals has a 52 week low of $0.92 and a 52 week high of $3.79.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.03. The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 8,311.12% and a negative return on equity of 137.53%. As a group, equities analysts forecast that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BVF Inc. IL grew its stake in Lexicon Pharmaceuticals by 22.2% in the 4th quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock worth $37,387,000 after buying an additional 4,440,300 shares in the last quarter. Pinnacle Associates Ltd. lifted its holdings in shares of Lexicon Pharmaceuticals by 1.0% in the 1st quarter. Pinnacle Associates Ltd. now owns 1,747,830 shares of the biopharmaceutical company’s stock worth $4,195,000 after acquiring an additional 17,009 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Lexicon Pharmaceuticals by 4.4% in the 3rd quarter. Swiss National Bank now owns 242,300 shares of the biopharmaceutical company’s stock worth $264,000 after acquiring an additional 10,300 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Lexicon Pharmaceuticals by 82.6% in the 1st quarter. BNP Paribas Financial Markets now owns 59,378 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 26,859 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter worth approximately $64,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.